¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15
±³À°ÀÏÀÚ : 2021-05-15
±³À°Àå¼Ò : ºí·ëºñ½ºÅ¸ ¾çÆò  
±³À°ÁÖÁ¦ : KGOG 2021 Semi-Annual Meeting
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5444  
À̸ÞÀÏ : koreagynonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 99¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 8 ½Ã°£ 56ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:00~08:15 Lesson model society NRG corpus: What is missing in KGOG?  Matthew A. Powell(NRG Uterine Corpus Committee Chair) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:15~08:30 Reasonable choice of target treatment among HER2(+) uterine cancer patients  Amanda Nickles Fader(Johns Hopkins Hospital) 
Åä·Ð 05-15 ±×·£µåº¼·ë 08:30~08:36 Discussion  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:36~08:39 Review of ongoing study- KGOG 2020: EM cancer, Fertility sparing high dose oral progestin ¿Ü  ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:39~08:42 Review of ongoing study-KGOG 2021 : TREE PRO  ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:42~08:45 Review of ongoing study-KGOG 2022 (NRG-GY018)  ±è¹ýÁ¾(¿øÀڷº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:45~08:48 Review of ongoing study-KGOG 2023  À̹æÇö(ÀÎÇϴ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:48~08:51 Review of ongoing study-KGOG 2024 : Phase II CR-GTP, pembroizumab  ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:51~08:54 Review of ongoing study-KGOG 2025 (AtEND)  ÀÌö¹Î(ÀÏ»êÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:54~08:57 Review of ongoing study-KGOG 2026: RACHEL PRO  ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:57~09:00 Review of ongoing study-KGOG 2027 (NRG-GY020)  ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:00~09:03 Review of ongoing study-KGOG 2028 : Radiation Oncology & GYN oncology patterns of survey  ±è¹Î±Ô(â¿ø»ï¼ºº´¿ø) 
Åä·Ð 05-15 ±×·£µåº¼·ë 09:03~09:08 Discussion  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:08~09:18 Proposal of new concepts- A. Sentinel lymph node (SNL) mapping for endometrial cancer  ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:18~09:28 Proposal of new concepts- Endometrial cancer screening of hysteroscopy with dye (Chromo- Hysteroscopy) in high-risk population (HysteroLynch )  ±è¹Î±Ô(â¿ø»ï¼ºº´¿ø) 
±âŸ 05-15 ±×·£µåº¼·ë 09:28~09:30 Closing  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 10:30~10:33 Cervix-Intorudction  À̱ÙÈ£(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 10:33~11:03 Review of ongoing study-KGOG 1028, 1036, 1037  Á¤¿ë¿í(°­³²Â÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:03~12:13 Proposal of new concepts A. Comparison of adjuvant radiotherapy versus observation in &quotintermediate risk" early cervical cancer patients after radical hysterectomy: Propensity score matching study  ½É½ÂÇõ(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:13~11:23 Proposal of new concepts Prediction model for survival and recurrence in early-stage cervical cancer patients with radical trachelectomy: A multicencer cohort study  ±è´ë¿¬(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:23~11:33 Proposal of new concepts DEBULK- Therapeutic effect of surgical debulking of metastatic LNs in cervical cancer stage IIIC before CCRT  ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:33~11:43 Proposal of new concepts Real world data of sentinel lymph node dissection in gynecologic cancer  ¼ÛÈñ°æ(¼­¿ï¼º¸ðº´¿ø) 
±âŸ 05-15 ±×·£µåº¼·ë 11:43~11:45 Closing  ±è»ó¿î(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 13:00~13:25 Niraparib in patients with newly diagnonsed advanced ovarian cancer : PRIMA trial  ±èÈñ½Â(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 13:25~13:50 Updated data of niraparib in Aasian patient  ¼ÛÇϳª(°æ»ó´ëº´¿ø) 
Åä·Ð 05-15 ±×·£µåº¼·ë 13:50~14:00 Discussion  () 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:00~14:08 Ovary-Introduction  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:08~14:13 Study Review of OV TSC-KGOG 3035(JGOG3020)  À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:13~14:18 Study Review of OV TSC-KGOG 3039(SUNNY): Sunny and Trust  ±èÀç¿ø(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:18~14:23 Study Review of OV TSC-KGOG 3042 IDSHIPEC: Current status of HIPEC in the GYN ONC community  Àå¼®ÁØ(¾ÆÁִ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:23~14:38 Study Review of OV TSC-KGOG 3045 AMBITION/3025 TRU-D : &quotFrom small Phase to pivotal study"  ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:38~14:43 Study Review of OV TSC-KGOG 3047 somatic mutational landscape of epithelial ovarian carcinoma and its clinical implications targeted next-generation sequencing: A multi-center study  ÀÌÁ¤¿ø(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:43~14:48 Study Review of OV TSC-KGOG 3048: Progress of KGOG 3048  ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:48~15:53 Study Review of OV TSC-KGOG 3049  À̹æÇö(ÀÎÇϴ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:53~14:58 Study Review of OV TSC-KGOG 3051(NRG-GY019): Management of low grade serous ovarian cancer  ÀÌÀ¯¿µ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:58~15:03 Study Review of OV TSC-KGOG 3053 (NRG-CC008)  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:03~15:08 Study Review of OV TSC-KGOG 3056: A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PAR inhibitor (Nirvana-R)  ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:08~15:18 Proposal of new concepts A. KGOG 3058: Effectiveness and safety of PARP-inhibitor maintenance therapy in recurrent ovarian cancer patients in real world Retrospective cohort study(ESPOIR)  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:18~15:28 Proposal of new concepts-OV 1908: A Phase I Clinical Trial of the Azacitidine(Azalid¢ç) with the Paclitaxel Polymeric Micelle (Genexol¢ç PM) in the treatment of patients with advanced or metastatic ovarian cancer  À̽ÅÈ­(¼­¿ï¾Æ»êº´¿ø) 
±âŸ 05-15 ±×·£µåº¼·ë 15:28~15:30 Closing  °­¼®¹ü(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 16:30~16:55 Clinical development of PARPi in ovarian cancer (past and future) and development of biomarkers of PARPi and HRD pathway  Richard Davidson(UK) 
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 16:55~17:20 Optimal front-line treatment with precision medicine in advanced ovarian cancer  ÀÌÀ¯¿µ(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 05-15 ±×·£µåº¼·ë 17:20~17:30 Discussion  () 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:00~12:03 Rare tumor-Introduction  ÃÖöÈÆ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:03~12:23 Mucinous carcinoma of GYN origin (intraepithelial mucinous carcinoma of ovary, gastric type cervical adenocarcinoma)  ±è±Ô·¡(¼­¿ï¾Æ»êº´¿ø º´¸®°ú) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:23~12:31 MIS vs. open surgery in rare histology cervical cancer  ±è¼¼ÀÍ(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:31~12:39 A MRI based machine learning approach for distinguishing uterine sarcoma from leiomyomas  ±èÅÂÈÆ(º¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:39~12:47 Radical vs. fertility sparing surgery in intraepithelial mucinous carcinoma of ovary  ½É½ÂÇõ(°Ç±¹´ëº´¿ø) 
±âŸ 05-15 Room B, C-302 È£ 12:47~12:49 Closing  ÃÖöÈÆ(»ï¼º¼­¿ïº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021³â ´ëÇÑ°í°üÀýÇÐȸ Áø·áÁöħ ½ÉÆ÷Áö¿ò : 2021-05-15
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦21ȸ Çѱ¹Æ÷µµ¸·ÇÐȸ ½ÉÆ÷Áö¾ö : 2021-05-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21030 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (2ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-28 0 5 2024-06-18
21029 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-28 0 4 2024-06-18
21028 ¼­¿ï 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-28 0 9 2024-06-18
21027 ºÎ»ê ´ëÇѽÉÀåÇÐȸ ±âÃÊ°úÇבּ¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö 2024 : 2024-06-28 0 6 2024-06-18
21026 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾƳ»ºÐºñÇÐȸ ºñ¸¸¿¬±¸Áý´ãȸ 2024³â 1Â÷ : 2024-06-27 0 5 2024-06-18
21025 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 3Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 2 2024-06-18
21024 ºÎ»ê Á¦11Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Ãá°èÁ¾ÇÕ½ÉÆ÷Áö¾ö 1ÀÏÂ÷ : 2024-06-27 0 4 2024-06-18
21023 ´ë±¸ ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ ´ë±¸°æºÏÁöȸ 3Â÷ Áý´ãȸ : 2024-06-27 0 4 2024-06-18
21022 ¼­¿ï ´ëÇѼҾƸ¶ÃëÇÐȸ ¿Â¶óÀÎ 2024³â Èñ±Í³­Ä¡ Áúȯ ¸¶Ãë ÇÁ·ÎÅäÄÝ ¿þºñ³ª : 2024-06-27 0 6 2024-06-18
21021 ¼­¿ï (1ÀÏÂ÷)2024³â ´ëÇÑô¼öÇÐȸ 2nd ISCoS Regional Symposium : 2024-06-27 0 6 2024-06-18
21020 °­¿ø 2024 ö¿ø±ºÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß(Ä¡¸Å, ¹é³»Àå°ú ³ë¾È) 0 6 2024-06-18
21019 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (1ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-27 0 2 2024-06-18
21018 ÀüºÏ ±º»ê½ÃÀÇ»çȸ ¿¬¼ö±³À°(±â´É¼º ¼ÒÈ­ºÒ·®Áõ, º¸Çè½É»çÀÇ ÃֽŠÀ̽´) : 2024-06-27 0 4 2024-06-18
21017 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 7 2024-06-18
21016 ºÎ»ê 2024 ±ÝÁ¤±¸ÀÇ»çȸ Çмú´ëȸ(¿¹¹æÁ¢Á¾, ÇʼöÀÇ·áÆÐÅ°Áö) : 2024-06-27 0 8 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷